US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MapLight Therapeutics, Inc.

17.89

+0.32001.82%

Post-market: 17.890.00000.00%16:10 EST

Volume:185.62K

Turnover:3.33M

Market Cap:811.72M

PE:-7.89

High:18.50

Open:17.49

Low:17.04

Close:17.57

52wk High:21.55

52wk Low:12.24

Shares:45.37M

Float Shares:15.23M

Volume Ratio:1.00

T/O Rate:1.22%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2660

EPS(LYR):-105.3781

ROE:--

ROA:--

PB:-2.96

PE(LYR):-0.17

Loading ...

Overview Company News Filings

Director Robert C. Malenka Reports Sale of Maplight Therapeutics Inc. Common Shares

Director Robert C. Malenka Reports Disposal of Maplight Therapeutics Inc. Common Shares

MapLight updates trial timelines and highlights CNS pipeline

MapLight Therapeutics Sets Q3 2026 for Phase 2 Trial Results in Schizophrenia and Autism

Maplight Therapeutics Inc - Zephyr Study Results Expected in Q3 2026

THOMSON REUTERS

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

FDA Grants Fast Track Designation to MapLight Therapeutics' ML-007C-MA for Alzheimer's Psychosis

Maplight Therapeutics Receives Fast Track Designation for Ml-007C-Ma for Alzheimer’s Disease Psychosis

THOMSON REUTERS

Aktis Oncology files for US IPO as biotech listings rebound

MapLight Therapeutics and SandboxAQ Partner to Develop Novel CNS Therapies

Maplight - Gains Exclusive Rights for Clinical Development, Commercialization of Collaboration Compounds

THOMSON REUTERS

Sandboxaq and Maplight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies

THOMSON REUTERS

Maplight Therapeutics Inc - Sandboxaq Eligible for up to $200 Mln in Milestone Payments

THOMSON REUTERS

BRIEF-Maplight Therapeutics Reports Third Quarter Financial Results

MapLight Therapeutics Q3 EPS $(37.18) Misses $(1.55) Estimate

MapLight Therapeutics Inc. Q3 net loss rises to USD 29.4 million, up 55 percent

Maplight Therapeutics Inc - Funds Sufficient to Operate Through 2027

THOMSON REUTERS

Maplight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

THOMSON REUTERS

Press Release: MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

Stifel Nicolaus Initiates Coverage on MapLight Therapeutics With Buy Rating, $28 Price Target

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MPLT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MPLT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","market":"US","secType":"STK","nameCN":"MapLight Therapeutics, Inc.","latestPrice":17.89,"timestamp":1770757200000,"preClose":17.57,"halted":0,"volume":185615,"hourTrading":{"tag":"盘后","latestPrice":17.89,"preClose":17.89,"latestTime":"16:10 EST","volume":3619,"amount":64743.91,"timestamp":1770757805259,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.018212862834376793,"floatShares":15226707,"shares":45373000,"eps":-2.266,"marketStatus":"Post-Mkt","change":0.32,"latestTime":"02-10 17:02:17 EST","open":17.49,"high":18.5,"low":17.035,"amount":3332571.5119,"amplitude":0.083381,"askPrice":19.75,"askSize":100,"bidPrice":17.5,"bidSize":9,"shortable":3,"etf":0,"ttmEps":-2.266,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770771600000},"marketStatusCode":4,"adr":0,"listingDate":1761537600000,"exchange":"NASDAQ","adjPreClose":17.57,"postHourTrading":{"tag":"盘后","latestPrice":17.89,"preClose":17.89,"latestTime":"16:10 EST","volume":3619,"amount":64743.91,"timestamp":1770757805259,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.004296},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","floatShares":15226707,"roa":"--","roe":"--","lyrEps":-105.378114,"volumeRatio":1.004296,"shares":45373000,"dividePrice":0,"high":18.5,"amplitude":0.083381,"preClose":17.57,"low":17.035,"week52Low":12.24,"pbRate":"-2.96","week52High":21.55,"institutionHeld":0,"latestPrice":17.89,"committee":-0.834862,"eps":-2.266,"divideRate":0,"volume":185615,"delay":0,"ttmEps":-2.266,"open":17.49,"prevYearClose":17.565,"prevWeekClose":16.98,"prevMonthClose":17.69,"prevQuarterClose":17.565,"fiveDayClose":17.11,"twentyDayClose":19.07,"sixtyDayClose":14.46},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MPLT\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MPLT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MPLT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.75,"buy":0.25,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.75,"analysts":4,"updateTime":1763960400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MPLT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MPLT","date":"2026-02-09","current":-7.753751,"percent":0.71831,"low":-8.946167,"twenty":-7.997597,"median":-7.581919,"eighty":-6.918981,"high":-6.048324,"avg":-7.503977,"sd":0.680487,"marketCap":741031345},"quantilePoints":[{"date":"2025-10-31","current":-8.673514,"twenty":-8.310978,"median":-7.61973,"eighty":-7.489746,"marketCap":801692922},{"date":"2025-11-07","current":-7.620605,"twenty":-8.035178,"median":-7.644213,"eighty":-7.545137,"marketCap":704372551},{"date":"2025-11-14","current":-6.742394,"twenty":-7.98511,"median":-7.554503,"eighty":-7.23627,"marketCap":623199506},{"date":"2025-11-21","current":-6.274959,"twenty":-7.73109,"median":-7.394197,"eighty":-6.810384,"marketCap":579994498},{"date":"2025-11-28","current":-6.435493,"twenty":-7.639491,"median":-7.190943,"eighty":-6.54881,"marketCap":594832581},{"date":"2025-12-05","current":-7.783335,"twenty":-7.714027,"median":-7.115398,"eighty":-6.435493,"marketCap":800383679},{"date":"2025-12-12","current":-8.528142,"twenty":-7.986054,"median":-7.394197,"eighty":-6.45249,"marketCap":876974375},{"date":"2025-12-19","current":-8.462361,"twenty":-8.266224,"median":-7.554503,"eighty":-6.54881,"marketCap":870209954},{"date":"2025-12-26","current":-7.689969,"twenty":-8.289163,"median":-7.620605,"eighty":-6.624355,"marketCap":790782566},{"date":"2026-01-02","current":-7.454432,"twenty":-8.20424,"median":-7.61973,"eighty":-6.670627,"marketCap":766561577},{"date":"2026-01-09","current":-7.295285,"twenty":-8.111814,"median":-7.53948,"eighty":-6.75706,"marketCap":750196044},{"date":"2026-01-16","current":-7.84275,"twenty":-8.074467,"median":-7.609335,"eighty":-6.818055,"marketCap":806493478},{"date":"2026-01-23","current":-7.885189,"twenty":-7.999774,"median":-7.554503,"eighty":-6.827382,"marketCap":810857620},{"date":"2026-01-30","current":-7.885189,"twenty":-8.004018,"median":-7.620167,"eighty":-6.893484,"marketCap":810857620},{"date":"2026-02-06","current":-6.662942,"twenty":-7.999774,"median":-7.609335,"eighty":-6.893484,"marketCap":685170325},{"date":"2026-02-09","current":-7.206163,"twenty":-7.997597,"median":-7.581919,"eighty":-6.918981,"marketCap":741031345}],"updateTime":1770733654730},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MPLT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609345991","title":"Director Robert C. Malenka Reports Sale of Maplight Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2609345991","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609345991?lang=en_us&edition=fundamental","pubTime":"2026-02-05 10:15","pubTimestamp":1770257735,"startTime":"0","endTime":"0","summary":"Robert C. Malenka, Director of Maplight Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDLbl6WXl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Director Robert C. Malenka Reports Sale of Maplight Therapeutics Inc. Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"gpt_icon":0},{"id":"2607078206","title":"Director Robert C. Malenka Reports Disposal of Maplight Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2607078206","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607078206?lang=en_us&edition=fundamental","pubTime":"2026-01-31 09:51","pubTimestamp":1769824289,"startTime":"0","endTime":"0","summary":"Robert C. Malenka, Director, reported a disposal of common shares of Maplight Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260131:nNDL1HjHYk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Robert C. Malenka Reports Disposal of Maplight Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"gpt_icon":0},{"id":"2602537538","title":"MapLight updates trial timelines and highlights CNS pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2602537538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602537538?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:29","pubTimestamp":1767961750,"startTime":"0","endTime":"0","summary":"An announcement from MapLight Therapeutics, Inc. ( ($MPLT) ) is now available. On January 9, 2026, MapLight Therapeutics announced it now expects t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maplight-updates-trial-timelines-and-highlights-cns-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maplight-updates-trial-timelines-and-highlights-cns-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MPLT","BK4135","CNS"],"gpt_icon":0},{"id":"2602781723","title":"MapLight Therapeutics Sets Q3 2026 for Phase 2 Trial Results in Schizophrenia and Autism","url":"https://stock-news.laohu8.com/highlight/detail?id=2602781723","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602781723?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:00","pubTimestamp":1767960013,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics Inc. announced updates on the expected timing of topline results for its ongoing Phase 2 clinical studies. The ZEPHYR trial, evaluating ML-007C-MA for the treatment of schizophrenia, is a randomized, double-blind, placebo-controlled study enrolling 300 hospitalized adult participants experiencing acute exacerbation of psychosis. Topline results for this trial are now expected in the third quarter of 2026. Additionally, the IRIS trial, a double-blind, placebo-controlled Phase 2 study of ML-004 in autism spectrum disorder with approximately 160 adult and adolescent participants, is also expected to report topline results in the third quarter of 2026. Results from both studies have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fina","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL3RbX2S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","LU2210149790.SGD","SG9999014021.USD","SG9999014039.USD","IE00BKPKM429.USD","LU2210150020.SGD","BK4112","MPLT","IE00BGHQF748.EUR","BK4588","NDAQ","SG9999014005.SGD","IE00B64PRP62.GBP","LU2095319765.USD","BK4139","LU0314104364.USD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2602921378","title":"Maplight Therapeutics Inc - Zephyr Study Results Expected in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602921378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602921378?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:00","pubTimestamp":1767960001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA5XLXF6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"gpt_icon":0},{"id":"2602373487","title":"MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602373487","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602373487?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:00","pubTimestamp":1767960000,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO and BOSTON, Jan.  09, 2026  (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/09/3215999/0/en/MapLight-Therapeutics-Updates-Expected-Timing-of-Topline-Results-for-Ongoing-Phase-2-Studies-to-Q3-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"gpt_icon":0},{"id":"2601885701","title":"FDA Grants Fast Track Designation to MapLight Therapeutics' ML-007C-MA for Alzheimer's Psychosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885701","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885701?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614425,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics Inc. announced that the U.S. Food and Drug Administration  has granted Fast Track designation to its investigational drug ML-007C-MA for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis . The Fast Track designation is intended to facilitate the development and expedite the review of therapies for serious conditions with unmet medical needs. ML-007C-MA is currently being evaluated in the ongoing Phase 2 VISTA clinical trial, with topline results expected in the second half of 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLc897H8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014005.SGD","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","LU2210149790.SGD","MPLT","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","BK4139","IE00BKPKM429.USD","BK4585","BK4112"],"gpt_icon":0},{"id":"2601885712","title":"Maplight Therapeutics Receives Fast Track Designation for Ml-007C-Ma for Alzheimer’s Disease Psychosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885712?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA692NCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"gpt_icon":0},{"id":"2592118076","title":"Aktis Oncology files for US IPO as biotech listings rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=2592118076","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592118076?lang=en_us&edition=fundamental","pubTime":"2025-12-20 06:45","pubTimestamp":1766184347,"startTime":"0","endTime":"0","summary":"Aktis Oncology files for US IPO as biotech listings reboundDec 19 (Reuters) - Aktis Oncology filed for an initial public offering in the United States on Friday, as stock market listings from the biot","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL6N3XP14T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052756011.USD","LU1069347547.HKD","BK4207","LU2129689431.USD","LU0130518102.USD","BK4585","LU0321505439.SGD","LU1162221912.USD","LU0203345920.USD","LU0149725797.USD","LU0306807586.USD","IE00BZ1G4Q59.USD","LU2265009873.SGD","LU0320765646.SGD","LU0868494617.USD","IE00BLSP4452.SGD","LU0310800965.SGD","LU1668664300.SGD","EVMN","LU1366192091.USD","LU1894683264.USD","LU1363072403.SGD","MNSH","LU0787776722.HKD","LU0256863902.USD","LU2133065610.SGD","LU1496350171.SGD","LU0971096721.USD","LU0417517546.SGD","BK4504","LU0256863811.USD","LU0208291251.USD","LU1880398554.USD","LU1883839398.USD","LU0170899867.USD","LBRX","LU0640476718.USD","BAC","BK4588","IE00BFXG1179.USD","LU0477156797.USD","LU0980610538.SGD","OWL","BK4139","IE00BBT3K403.USD","BK4559","LU0203347892.USD","IE0002270589.USD","MPLT","LU0306806265.USD"],"gpt_icon":0},{"id":"2591989403","title":"MapLight Therapeutics and SandboxAQ Partner to Develop Novel CNS Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2591989403","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591989403?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:01","pubTimestamp":1765886466,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics Inc. has entered into a strategic collaboration with SandboxAQ to discover and develop novel therapies targeting a G protein-coupled receptor  for central nervous system  disorders. Under the agreement, SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments. The partnership will combine MapLight's CNS expertise with SandboxAQ's advanced AI and molecular simulation technologies to accelerate the discovery and optimization of potential first-in-class drug candidates. MapLight will have exclusive rights to clinical development and commercialization of compounds resulting from the collaboration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. publish","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL1fhtdk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014005.SGD","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","LU2210149790.SGD","MPLT","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","BK4139","IE00BKPKM429.USD","BK4585","BK4112"],"gpt_icon":0},{"id":"2591989766","title":"Maplight - Gains Exclusive Rights for Clinical Development, Commercialization of Collaboration Compounds","url":"https://stock-news.laohu8.com/highlight/detail?id=2591989766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591989766?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:00","pubTimestamp":1765886401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA5VTB5J:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"gpt_icon":0},{"id":"2591989457","title":"Sandboxaq and Maplight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2591989457","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591989457?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:00","pubTimestamp":1765886401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA5VTB5J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"gpt_icon":0},{"id":"2591768989","title":"Maplight Therapeutics Inc - Sandboxaq Eligible for up to $200 Mln in Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2591768989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591768989?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:00","pubTimestamp":1765886401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA5VTB5J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"gpt_icon":0},{"id":"2588688058","title":"BRIEF-Maplight Therapeutics Reports Third Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2588688058","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588688058?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:15","pubTimestamp":1764857755,"startTime":"0","endTime":"0","summary":"BRIEF-Maplight Therapeutics Reports Third Quarter Financial Results Dec 4 (Reuters) - Maplight Therapeutics Inc MPLT.O:MAPLIGHT THERAPEUTICS REPORTS THIRD QUARTER FINANCIAL RESULTS AND HIGHLIGHTS CORP","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA19HGS8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"gpt_icon":0},{"id":"2588884709","title":"MapLight Therapeutics Q3 EPS $(37.18) Misses $(1.55) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2588884709","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588884709?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:06","pubTimestamp":1764853584,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(37.18) per share which missed the analyst consensus estimate of $(1.55) by 2291 percent. This is a 48.25 percent decrease over losses of $(25.08) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/12/49205968/maplight-therapeutics-q3-eps-37-18-misses-1-55-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT"],"gpt_icon":0},{"id":"2588889639","title":"MapLight Therapeutics Inc. Q3 net loss rises to USD 29.4 million, up 55 percent","url":"https://stock-news.laohu8.com/highlight/detail?id=2588889639","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588889639?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:00","pubTimestamp":1764849640,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics Inc. reported its third quarter  2025 financial results. Research and development expenses for Q3 2025 totaled USD 27.1 million, an increase of 61 percent, primarily driven by higher clinical trial, employee-related, and formulation and CMC expenses. General and administrative expenses for the period were USD 4.4 million. Total operating expenses reached USD 31.5 million for Q3 2025. Net loss for the quarter was USD 29.4 million. For the nine-month period ended September 30, 2025, research and development expenses were USD 73.7 million and general and administrative expenses were USD 12.0 million. Total operating expenses for the nine-month period amounted to USD 85.7 million. The company also reported that it raised USD 296.5 million in gross proceeds from its initial public offering and concurrent private placement in October 2025, and that cash, cash equivalents, and short-term investments are sufficient to fund operations through 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL2KHp8n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0314104364.USD","BK4588","MPLT","LU2095319765.USD","IE00BKPKM429.USD","NDAQ","BK4585","BK4139","LU2210150020.SGD"],"gpt_icon":0},{"id":"2588896498","title":"Maplight Therapeutics Inc - Funds Sufficient to Operate Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2588896498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588896498?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:00","pubTimestamp":1764849603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA19HGS8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"gpt_icon":0},{"id":"2588543889","title":"Maplight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2588543889","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588543889?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:00","pubTimestamp":1764849603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA19HGS8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"gpt_icon":0},{"id":"2588889324","title":"Press Release: MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2588889324","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588889324?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:00","pubTimestamp":1764849600,"startTime":"0","endTime":"0","summary":"-- Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia. -- Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer's. disease psychosis expected in the second half of 2027. -- Raised $296.5 million in gross proceeds from initial public offering and. -- Cash, cash equivalents and short-term investments sufficient to fund. \"2025 was a year of exceptional execution and acceleration for MapLight, \" said Chris Kroeger, Chief Executive Officer of MapLight Therapeutics. \"In the last year, we have made noteworthy progress across our entire product candidate portfolio, including the initiation of the Phase 2 ZEPHYR and VISTA studies for ML-007C-MA, completion of enrollment in our Phase 2 IRIS study of ML-004 and advancement of our preclinical programs. With a strengthened balance sheet following our recent public offering, we are in a strong financial position to continue this momentum to advance our broad and diversified pipeline of potentially best-in-class ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1236620834.HKD","LU1934455194.USD","IE00BFXG0V08.USD","LU0965508806.USD","LU2506952097.USD","LU1037948897.HKD","LU0345774631.USD","LU1221951129.SGD","LU1236620750.USD","LU0690374615.EUR","LU0965509101.SGD","GB00B4QBRK32.GBP","LU0950375773.USD","LU0345774391.USD","IE00BYQQ9H92.USD","IPO","LU1032955483.USD","ADP","BK4588","BK4139","BK4106","BK4097","BK4528","LU2404859667.USD","BK4613","LU2404859741.USD","LU1691799644.USD","LU0965509010.AUD","LU2506951875.HKD","LU0823417653.USD","LU1196500208.SGD","BK4130","GB00B4LPDJ14.GBP","LU0965509283.SGD","LU2065732104.USD","LU1221951046.USD","LU0861579265.USD","LU2506952170.USD","LU2506951958.HKD","LU0823417737.USD","MPLT","IE00B5TLWC47.USD","LU1228905037.USD","LU0690374961.EUR","LU1228905540.USD","PRGS","LU0289941410.SGD","BK4585","LU1037948541.HKD","LU1934455863.HKD"],"gpt_icon":0},{"id":"2585485621","title":"Stifel Nicolaus Initiates Coverage on MapLight Therapeutics With Buy Rating, $28 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2585485621","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585485621?lang=en_us&edition=fundamental","pubTime":"2025-11-21 20:29","pubTimestamp":1763728197,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus Initiates Coverage on MapLight Therapeutics With Buy Rating, $28 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SF","MPLT"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":46,"code":"91000000","status":"200"}]}}